BT3 Biotime

BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference

BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the Ladenburg Thalmann 2016 Healthcare Conference in New York City on Tuesday, September 27, 2016, at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time.

The Ladenburg Thalmann Healthcare Conference is a well-respected event for investors who are specifically focused on healthcare and life sciences companies such as BioTime. This venue allows BioTime’s management to provide a corporate overview and update on its product development.

Attendance is by invitation only. However, the presentation will be webcast live and will also be available for replay at the “Events & Presentations” page of the “Investors & Media” section on BioTime’s website at http://www.biotimeinc.com/.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent cell assets. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

EN
23/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biotime

 PRESS RELEASE

Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeuti...

Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s shares to trade under new ticker symbol “ERNA” starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeuti...

 PRESS RELEASE

Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-...

Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and fifty patients were enrolled ...

 PRESS RELEASE

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification R...

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq...

 PRESS RELEASE

Brooklyn ImmunoTherapeutics Announces Board Changes

Brooklyn ImmunoTherapeutics Announces Board Changes SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022: Matt Angel, Ph.D., Interim Chief Executive Officer (“CEO”) of Brooklyn and Co-Founder, Chairman, President and CEO of Factor Bioscience Inc.Gregory Fiore, Co-Fo...

 PRESS RELEASE

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management:...

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chai...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch